Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

3selected

Field	TICAGRELOR Haematology · Haematology · Level 2	PRASUGREL Haematology · Haematology · Level 2	TIROFIBAN Haematology · Haematology · Level 3
Mechanism of action	Allosteric, reversible antagonist at P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking	Irreversibly binds the P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking	Antagonises the GpIIb/IIIa receptor, preventing the binding of fibrinogen and platelet crosslinking and aggregation.
Absorption	BA=40%	—	—
Metabolism	Metabolized by CYP3A4	Prodrug- 1 step metabolism Less susceptible to CYP polymorphism and CYP inhibition or induction than Clopidogrel	Limited metabolism in humans.
Excretion	—	—	Excreted in urine and faeces, mostly unchanged
Half-life	—	—	HL 1.9-2.2 hrs
Adverse Effects Toxicity	—	—	Haemorrhage Difficulty reversing agent Dose adjustment in renal impairment
Class Group	Antiplatelet	Antiplatelet	Antiplatelet
Introduction	ADP Receptor Antagonist - Thienopyridine	ADP Receptor Antagonist - Thienopyridine Prodrug	GP IIb/IIIA Inhibitor
Legacy Cicm Level	Level 3	Level 3	Level 3
Main Action	Platelet inhibition	Platelet inhibition	Platelet inhibition